Stocklytics Platform
Asset logo for symbol CVRX
CVRx
CVRX63
$9.70arrow_drop_up13.98%$1.19
Penny Stock
Asset logo for symbol CVRX
CVRX63

$9.70

arrow_drop_up13.98%

AI Deep-Learning Forecast (CVRX)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

CVRx (CVRX) Stocklytics Forecast

CVRx, Inc. (CVRX) is a medical device company that specializes in developing innovative therapies for the treatment of cardiovascular diseases. The company's flagship product is the Barostim Neo System, an implantable device that delivers electrical signals to the carotid sinus to regulate blood pressure. With a strong focus on research and development, CVRx is at the forefront of cardiovascular therapy advancements.

Looking ahead, the stock price prediction for CVRx, Inc. (CVRX) shows positive prospects. Analysts and AI-powered algorithms forecast steady growth for the company. The machine learning prediction for CVRX suggests that the stock has the potential to increase in value. Additionally, analysts have set a price target for CVRx, Inc., indicating their optimistic outlook for the stock.

add CVRx to watchlist

Keep an eye on CVRx

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the analyst price prediction for CVRx (CVRX) stock?

Analysts have set a target price of $21.53 for CVRx (CVRX), based on forecasts from 15 analysts. The predicted price range extends from a high of $36 to a low of $13. This represents a potential increase of up to 271.13% and a decrease of 34.02% from the current price of $9.7. These forecasts are as of 2021 Jul 26.

help
What are the analyst ratings for CVRx (CVRX) stock?

Currently, there are no analyst ratings available for CVRx (CVRX), possibly due to insufficient coverage or recent updates.

help
What is the AI price prediction for CVRx (CVRX) stock?

At present, there is no AI or machine-learning-based price prediction available for CVRx (CVRX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level